Perphenazine is a typical (first-generation) antipsychotic drug belonging to the phenothiazine class, introduced in the 1950s for the treatment of schizophrenia and other psychotic disorders. Its history is marked by its effectiveness in controlling positive symptoms of psychosis such as hallucinations, delusions, and severe agitation, which significantly improved psychiatric care before the development of atypical antipsychotics. Perphenazine acts primarily by blocking dopamine D2 receptors in the mesolimbic pathway of the brain, thereby reducing dopaminergic overactivity associated with psychotic symptoms. It is also used in some cases for severe nausea and vomiting due to its antiemetic properties. Over time, its use has declined compared to newer antipsychotics, but it remains an important option in specific clinical situations.
BRAND NAMES
Trilafon (most well-known brand)
Perphenazine Tablets (generic branded formulations)
Trilafon Decanoate (long-acting injectable form in some regions)
MECHANISM OF ACTION
Perphenazine is a typical antipsychotic (phenothiazine) that primarily works by blocking dopamine D2 receptors in the central nervous system, especially in the mesolimbic pathway. This dopamine receptor antagonism reduces dopaminergic overactivity, which is associated with positive symptoms of schizophrenia such as hallucinations, delusions, and agitation.
PHARMACOKINETICS
Absorption
Perphenazine is well absorbed after oral administration, although its systemic bioavailability is variable due to first-pass hepatic metabolism. Peak plasma concentrations are typically reached within 2 to 4 hours after oral dosing. It can be taken with or without food, but food may slightly delay absorption without affecting overall extent.
Distribution
Perphenazine is widely distributed throughout body tissues, including the brain, due to its lipophilic nature. It is highly protein bound (about 90% or more) in plasma. The drug crosses the blood–brain barrier and also passes into breast milk.
Metabolism
Perphenazine is extensively metabolized in the liver, mainly via oxidation and conjugation pathways, including involvement of CYP2D6 enzymes. It is converted into several inactive metabolites, though genetic variability in metabolism can affect drug levels.
Elimination
The drug and its metabolites are eliminated primarily through the urine and feces. The elimination half-life varies widely, typically ranging from 8 to 12 hours, but may be longer in slow metabolizers or in hepatic impairment.
PHARMACODYNAMICS
Perphenazine is a typical antipsychotic (phenothiazine) that exerts its effects mainly through dopamine D2 receptor antagonism in the mesolimbic pathway of the brain. This reduces excessive dopaminergic activity responsible for psychotic symptoms such as hallucinations and delusions. It also has secondary antagonistic effects on histamine H1, muscarinic cholinergic, and alpha-1 adrenergic receptors, contributing to sedation, antiemetic effects, and side effects such as dry mouth, hypotension, and sedation.
ADMINISTRATION
Perphenazine is administered orally in tablet form and is also available as a long-acting injectable (decanoate form) for maintenance therapy in chronic psychiatric conditions. It is usually taken one to several times daily depending on clinical response.
DOSAGE AND STRENGTH
Dosage varies depending on the condition. For schizophrenia, typical oral doses range from 4 mg to 64 mg per day, divided into multiple doses. Long-acting injectable formulations are administered every 2–4 weeks depending on response.
DRUG INTERACTIONS
Perphenazine may interact with CNS depressants (alcohol, benzodiazepines, opioids), increasing sedation. It can enhance the effects of antihypertensive drugs, leading to hypotension. Drugs that inhibit CYP2D6 (such as fluoxetine or paroxetine) may increase perphenazine levels and toxicity risk.
FOOD INTERACTIONS
Perphenazine has no major food restrictions, but alcohol should be avoided due to increased sedation and CNS depression.
CONTRAINDICATIONS
Contraindications include hypersensitivity to perphenazine or other phenothiazines, severe CNS depression, coma, and severe bone marrow suppression. It should be used cautiously in patients with Parkinson’s disease, liver impairment, or seizure disorders.
SIDE EFFECTS
Common side effects include drowsiness, dizziness, dry mouth, blurred vision, constipation, and weight gain. Extrapyramidal symptoms such as tremor, rigidity, dystonia, and tardive dyskinesia may also occur. Orthostatic hypotension and photosensitivity are additional possible effects.
OVER DOSAGE
Perphenazine overdose can cause severe central nervous system depression and extrapyramidal symptoms. Patients may present with extreme drowsiness, confusion, agitation, restlessness, or coma. Neuromuscular effects such as muscle rigidity, tremors, dystonia, and involuntary movements may also occur due to excessive dopamine blockade.
TOXICITY
Perphenazine overdose or toxicity may lead to severe extrapyramidal symptoms, profound sedation, hypotension, respiratory depression, and coma. Neuroleptic malignant syndrome (NMS), a rare but life-threatening reaction, may also occur. Management includes supportive care, airway protection, and symptomatic treatment, including anticholinergic agents for extrapyramidal symptoms.
